Related Experiment Videos
Recent developments and perspectives of biotechnology-derived products
1Department of Pharmacology, University of Texas Health Science Center, San Antonio, USA.
Toxicology
|December 20, 1995
Summary
Advances in molecular biology enable new biopharmaceuticals like antisense drugs and cytokines. Safety, efficacy, manufacturing, and regulatory challenges must be addressed for these complex therapeutic agents.
Area of Science:
- Molecular biology
- Biotechnology
- Pharmacology
Background:
- Recent molecular biology advancements, including recombinant DNA (rDNA) technology, gene transfer, polymerase chain reaction (PCR), and hybridoma techniques, have yielded novel molecular tools.
- These tools facilitate the development of a new generation of biopharmaceuticals with diverse therapeutic applications.
Purpose of the Study:
- To highlight the emergence of novel biopharmaceuticals driven by molecular biology.
- To identify key challenges in the development and regulation of these complex therapeutic agents.
Main Methods:
- Review of recent advances in molecular biology techniques.
- Identification of emerging biopharmaceutical classes.
- Discussion of safety, efficacy, manufacturing, quality control, and regulatory considerations.
Main Results:
- New biopharmaceutical classes include antisense drugs, carbohydrate-based macromolecules, apoptosis-interfering agents, cytokines, and immunomodulators.
- Significant challenges exist in evaluating the safety, efficacy, manufacturing, and quality control of these complex products.
Conclusions:
- Molecular biology has revolutionized biopharmaceutical development, offering promising new therapies.
- Addressing the pharmacological, toxicological, and regulatory complexities is crucial for ensuring the safety and availability of these evolving therapeutic substances.